Joseph Jimenez of Novartis
Solid financial performance in the second quarter of 2010 for the Swiss pharmaceutical company Novartis: revenues grow by 11% (+12% in constant currency, vc) to 11.7 billion dollars. Earnings per share (Eps) recorded an increase of 18% (+17% in cc), to 1.06 dollars, while, net of exceptional events, it grew by 14% (+14% in cc), to 1.20 dollars.
Group volumes grew by up to 12 percentage points, prices detracted by one point and acquisitions contributed by one point. Pharmaceuticals ($7.7B, +8%) made progress across all regions and confirmed solid growth in volumes. Vaccines & Diagnostics ($0.6 billion, +135%) posted a substantial increase, including $0.2 billion from rights to sell the pandemic A(H1N1) vaccine. Sandoz ($2 billion, +13%) grows on successful new product launches and contribution from Ebewe Pharma. All Consumer Health businesses ($1.5 billion, +7%) delivered solid performances.
As for half-yearly revenues, the figure is up by 18% (+15% in vc), to 23.8 billion dollars, while EPS grows in the first six months of the year by 33% (+28%) to 2.34 dollars . Eps net of exceptional events increased by 29% (+24% in cv), to 2.65 dollars.
Commenting on the results, Novartis Chief Executive Officer Joseph Jimenez said, "I am pleased that, in the second quarter of 2010, Novartis once again delivered solid double-digit growth, outpacing the market. These results were driven by our successes in innovation, with recently launched products contributing 21% to Group revenue.
We are making significant progress on each of our three strategic priorities: innovation, growth and productivity."
(BDC) Pharmakronos – July 16, 2010 
Novartis net income up +19% in Q2 2010
In Q2 2010 Novartis reported a 19% increase in
